Advertisement

Der Hautarzt

, Volume 70, Issue 1, pp 15–20 | Cite as

Personalisierte Medizin im Bereich entzündlicher Hauterkrankungen

  • N. Garzorz-StarkEmail author
  • K. Eyerich
Leitthema
  • 93 Downloads

Zusammenfassung

Hintergrund

Für eine ausreichende Versorgung von Patienten mit chronisch entzündlichen Hauterkrankungen müssen neue Konzepte entwickelt und Biomarker identifiziert werden.

Fragestellung

Dargestellt werden neue Marker sowie deren Qualität und Implikation für den klinischen Alltag.

Material und Methode

Es erfolgen die Diskussion von Grundlagenarbeiten und die Zusammenfassung neuer Entwicklungen der personalisierten Medizin im Bereich chronisch entzündlicher Hauterkrankungen.

Ergebnisse

Vielversprechende Biomarker für unterschiedliche Entitäten des chronisch entzündlichen Formenkreises wurden bereits vorgeschlagen, bedürfen jedoch einer prospektiven Validierung und Umsetzung in kostengünstige, praktikable Tests.

Schlussfolgerungen

Der Weg zur personalisierten Medizin im Gebiet der chronisch entzündlicher Hauterkrankungen ist noch weit und bedarf nicht zuletzt einer multizentrischen Kollaboration zur Validierung und Implementierung von Biomarkern.

Schlüsselwörter

Biomarker Psoriasis Ekzem Validierung Implementierung  

Personalized medicine in the field of inflammatory skin diseases

Abstract

Background

For sufficient treatment of patients with chronic inflammatory skin diseases, new concepts need to be established and biomarkers must be identified.

Objective

Presentation of new markers, their quality and implications for the clinical daily routine.

Material and methods

This article presents a discussion of basic research and a review of current achievements of personalized medicine in the area of chronic inflammatory skin diseases.

Results

Promising biomarker for the various entities of chronic inflammatory skin diseases have been proposed; however, they need to be prospectively validated and translated into affordable and feasible tests.

Conclusion

There is still a long way to go to establish personalized medicine in the field of chronic inflammatory skin diseases and its success is dependent on multicenter collaboration to validate and implement novel biomarkers.

Keywords

Biomarkers Psoriasis Eczema Validation Implementation 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

N. Garzorz-Stark und K. Eyerich geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Fadzil AMH, Ihtatho D, Mohd Affandi A et al (2009) Objective assessment of psoriasis erythema for PASI scoring. J Med Eng Technol 33:516–524CrossRefGoogle Scholar
  2. 2.
    Bai F, Zheng W, Dong Y et al (2018) Serum levels of adipokines and cytokines in psoriasis patients: a systematic review and meta-analysis. Oncotarget 9:1266–1278PubMedGoogle Scholar
  3. 3.
    Berekmeri A, Latzko A, Alase A et al (2018) Detection of IL-36gamma through noninvasive tape stripping reliably discriminates psoriasis from atopic eczema. J Allergy Clin Immunol 142:988–91e4CrossRefGoogle Scholar
  4. 4.
    Brunner PM, Pavel AB, Khattri S et al (2018) Baseline IL22 expression in atopic dermatitis patients stratifies tissue responses to fezakinumab. J Allergy Clin Immunol.  https://doi.org/10.1016/j.jaci.2018.07.028 CrossRefPubMedGoogle Scholar
  5. 5.
    Chan TC, Sanyal RD, Pavel AB et al (2018) Atopic dermatitis in Chinese patients shows TH2/TH17 skewing with psoriasiform features. J Allergy Clin Immunol 142:1013–1017CrossRefGoogle Scholar
  6. 6.
    Charman CR, Venn AJ, Williams HC (1999) Measurement of body surface area involvement in atopic eczema: an impossible task? Br J Dermatol 140:109–111CrossRefGoogle Scholar
  7. 7.
    Coto-Segura P, Batalla A, Gonzalez-Fernandez D et al (2015) CDKAL1 gene variants affect the anti-TNF response among Psoriasis patients. Int Immunopharmacol 29:947–949CrossRefGoogle Scholar
  8. 8.
    D’Erme AM, Wilsmann-Theis D, Wagenpfeil J et al (2015) IL-36gamma (IL-1F9) is a biomarker for psoriasis skin lesions. J Invest Dermatol 135:1025–1032CrossRefGoogle Scholar
  9. 9.
    Eyerich K, Eyerich S (2018) Immune response patterns in non-communicable inflammatory skin diseases. J Eur Acad Dermatol Venereol 32:692–703CrossRefGoogle Scholar
  10. 10.
    Garzorz-Stark N, Krause L, Lauffer F et al (2016) A novel molecular disease classifier for psoriasis and eczema. Exp Dermatol 25:767–774CrossRefGoogle Scholar
  11. 11.
    Guinot C, Latreille J, Perrussel M et al (2009) Psoriasis: characterization of six different clinical phenotypes. Exp Dermatol 18:712–719CrossRefGoogle Scholar
  12. 12.
    Guttman-Yassky E, Suarez-Farinas M, Chiricozzi A et al (2009) Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis. J Allergy Clin Immunol 124:1235–1244.e58CrossRefGoogle Scholar
  13. 13.
    Hulshof L, Hack DP, Hasnoe QCJ et al (2018) Stratum corneum analysis provide a minimal invasive tool to study immune response and skin barrier in atopic dermatitis children. Br J Dermatol  https://doi.org/10.1111/bjd.16994. [Epub ahead of print]CrossRefPubMedGoogle Scholar
  14. 14.
    Inkeles MS, Scumpia PO, Swindell WR et al (2014) Comparison of molecular signatures from multiple skin diseases identifies mechanisms of immunopathogenesis. J Invest Dermatol.  https://doi.org/10.1038/jid.2014.352 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Jacobi A, Antoni C, Manger B et al (2005) Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 52:522–526CrossRefGoogle Scholar
  16. 16.
    Jansen PA, Rodijk-Olthuis D, Hollox EJ et al (2009) Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin. PLoS ONE 4:e4725CrossRefGoogle Scholar
  17. 17.
    Jin T, Sun Z, Chen X et al (2017) Serum human beta-defensin-2 is a possible biomarker for monitoring response to JAK inhibitor in psoriasis patients. Dermatology 233:164–169CrossRefGoogle Scholar
  18. 18.
    Krause L, Mourantchanian V, Brockow K et al (2016) A computational model to predict severity of atopic eczema from 30 serum proteins. J Allergy Clin Immunol 138:1207–1210e2CrossRefGoogle Scholar
  19. 19.
    Meggitt SJ, Gray JC, Reynolds NJ (2006) Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet 367:839–846CrossRefGoogle Scholar
  20. 20.
    Quaranta M, Knapp B, Garzorz N et al (2014) Intraindividual genome expression analysis reveals a specific molecular signature of psoriasis and eczema. Sci Transl Med 6(244):244ra90.  https://doi.org/10.1126/scitranslmed.3008946 CrossRefGoogle Scholar
  21. 21.
    Sazanovs et al (2018) HLA-DQA1 contributes to the development of antibodies to anti-TNF therapy in Crohn’s disease. ECCO 2018 conference OP013.Google Scholar
  22. 22.
    Suarez-Farinas M, Dhingra N, Gittler J et al (2013) Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J Allergy Clin Immunol 132:361–370CrossRefGoogle Scholar
  23. 23.
    Thijs J, Krastev T, Weidinger S et al (2015) Biomarkers for atopic dermatitis: a systematic review and meta-analysis. Curr Opin Allergy Clin Immunol 15:453–460CrossRefGoogle Scholar
  24. 24.
    Thijs JL, Nierkens S, Herath A et al (2015) A panel of biomarkers for disease severity in atopic dermatitis. Clin Exp Allergy 45:698–701CrossRefGoogle Scholar
  25. 25.
    Ungar B, Garcet S, Gonzalez J et al (2017) An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease. J Invest Dermatol 137:603–613CrossRefGoogle Scholar
  26. 26.
    Watson JD, Crick FH (1953) Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid. Nature 171:737–738CrossRefGoogle Scholar
  27. 27.
    Wenzel J, Peters B, Zahn S et al (2008) Gene expression profiling of lichen planus reflects CXCL9+-mediated inflammation and distinguishes this disease from atopic dermatitis and psoriasis. J Invest Dermatol 128:67–78CrossRefGoogle Scholar
  28. 28.
    Wolk K, Frambach Y, Jacobi A et al (2018) Increased levels of lipocalin 2 in palmoplantar pustular psoriasis. J Dermatol Sci 90:68–74CrossRefGoogle Scholar
  29. 29.
    Wolk K, Wenzel J, Tsaousi A et al (2017) Lipocalin-2 is expressed by activated granulocytes and keratinocytes in affected skin and reflects disease activity in acne inversa/hidradenitis suppurativa. Br J Dermatol 177:1385–1393CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Klinik und Poliklinik für Dermatologie und Allergologie am BiedersteinTU MünchenMünchenDeutschland

Personalised recommendations